Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is an extremely lethal disease due to late diagnosis, aggressiveness and lack of effective therapies. Considering its intrinsic heterogeneity, patient stratification models based on transcriptomic and genomic signatures, with partially overlapping subgroups, have been established. Besides molecular alterations, PDAC tumours show a strong desmoplastic response, resulting in profound metabolic reprogramming involving increased glucose and amino acid consumption, as well as lipid scavenging and biosynthesis. Interestingly, recent works have also revealed the existence of metabolic subtypes with differential prognosis within PDAC, which correlated to defined mol...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Pancreatic Ductal Adenocarcinomas initiates in the exocrine part of the pancreatic tissue and repres...
Pancreatic Ductal Adenocarcinomas initiates in the exocrine part of the pancreatic tissue and repres...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Although significant advances have been made recently to characterize the biology of pan...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Pancreatic ductal adenocarcinoma (PDAC) is a major research focus because of its poor therapy respon...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Pancreatic Ductal Adenocarcinomas initiates in the exocrine part of the pancreatic tissue and repres...
Pancreatic Ductal Adenocarcinomas initiates in the exocrine part of the pancreatic tissue and repres...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Although significant advances have been made recently to characterize the biology of pan...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Pancreatic ductal adenocarcinoma (PDAC) is a major research focus because of its poor therapy respon...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a ...